Warfarin sensitivity genotyping: A review of the literature and summary of patient experience

Mayo Clinic Proceedings

Volumn 84, Issue 12, 2009, Pages 1079-1094

  Moyer, Thomas P ^a   O'Kane, Dennis J ^a   Baudhuin, Linnea M ^a   Wiley, Carmen L ^b   Fortini, Alexandre ^c   Fisher, Pamela K ^a   Dupras, Denise M ^a   Chaudhry, Rajeev ^a   Thapa, Prabin ^a   Zinsmeister, Alan R ^a   Heit, John A ^a  

^a MAYO CLINIC   (United States)

^b SACRED HEART MEDICAL CENTER   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 2C9; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; ETHNICITY; EUROPEAN AMERICAN; GASTROINTESTINAL HEMORRHAGE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PATIENT SATISFACTION; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; STROKE; THROMBOEMBOLISM;

EID: 72949112021     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0278     Document Type: Article

References (79)

1. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest. 2008;133(suppl 6):160S-198S.
2. Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. BJH. 2006;136:26-29.
3. Flockhart DA, O'Kane D, Williams MS, et al; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10(2):139-150.
4. Husted SE, Ziegler BK, Kher A. Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J. 2006 Apr;27(8):913-919. Epub 2006 Jan 9.
5. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: evidence-based clinical practice guidelines, American College of Chest Physicians (8th Edition). Chest. 2008;133(6 suppl):546S-592S.
6. McWilliams A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case of warfarin. Working Paper 06-23 November 2006. http://www.reg-markets.org/publications/abstract. php?pid=1127. Accessed September 3, 2009.
7. Marketos M. The top 200 generic drugs in 2003 (by unit). Drug Topics. 2004 Mar 8;148:82.
8. Reynolds K, Valdes Jr R, Hartung BR, Linder MW. Individualizing warfarin therapy. Per Med. 2007;4(1):11-31.
9. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858-1866.
10. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med. 1993;153(13):1557-1562.
11. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vanden-broucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333(1):11-17.
12. Palareti G, Leali N, Coccheri S, et al; Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulation treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348(9025):423-428.
13. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95(3):315-328.
14. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulation therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70(8):725-733.
15. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160(7):967-973.
16. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927-934.
17. Hirschl M, Pluschnig U, Kundi M, Katzenschlager R. Oral anticoagulation in older patients with vascular or cardiovascular diseases: aged over 70 years: same risk? Same benefit? Int Angiol. 2003;22(4):370-375.
18. Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulation management by anticoagulation clinics and by family physicians: a randomized controlled trial [published correction appears in CAMJ. 2004;170(4):451]. CMAJ. 2003;169(4):293-298.
19. Wallvik J, Själander A, Johansson L, Bjuhr R, Jansson JH. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care. 2007;25(2):123-128.
20. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130(5):1390-1396.
21. Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007 Jun;120(6):539-544. Epub 2007 Apr 26.
22. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of antico-agulant-associated intracerebral hemorrhage. Neurology. 2007;68(2):116-121.
23. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167(13):1414-1419.
24. Leigh JP, White RH. An economic model of adverse events and the costs for oral anticoagulants used for atrial fibrillation. Curr Med Res Opin. 2007;23(9):2071-2081.
25. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009 Jan;40(1):235-240. Epub 2008 Aug 28.
26. Gattellari M, Worthington J, Zwar N. Warfarin: an inconvenient truth [editorial]. Stroke. 2009 Jan;40(1):5-7. Epub 2008 Aug 28.
27. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin. Ann Intern Med. 2009;150(5):293-300.
28. Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost. 1983;49(3):238-244.
29. Furie B, Liebman HA, Blanchard RA, Coleman MS, Kruger SF, Furie BC. Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy. Blood. 1984;64(2):445-451.
30. Kornberg A, Francis CW, Pellegrini VD Jr, Gabriel KR, Marder VJ. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation. 1993;88(2): 454-460.
31. Le DT, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI. The International Normalized Ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med. 1994;120(7): 552-558.
32. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348(9028):633-638.
33. Health Care Guideline Institute for Clinical Systems Improvement Web site. Antithrombotic therapy supplement (guideline). September 2007: http://www.icsi.org/guidelines-and-more/gl-os-prot/cardiovascular/ antithrombotic-therapy-supplement--guideline--14045/antithrombotic-therapy- supplement-guideline.html. Accessed September 4, 2009.
34. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005 Jul 1;14(13):1745-1751. Epub 2005 May 11.
35. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008 Aug 15;112(4):1013-1021. Epub 2008 Jun 3.
36. Kealey C, Chen Z, Christie J, et al. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics. 2007;8(3):217-225.
37. Schelleman H, Chen Z, Kealey C, et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther. 2007 May;81(5):742-747. Epub 2007 Feb 28.
38. Kimmel SE, Christie J, Kealey C, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 2008 Feb;8(1):53-60. Epub 2007 Feb 27.
39. Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp-36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007 Mar 15;109(6):2477-2480. Epub 2006 Nov 16.
40. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717-719.
41. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96(5):1816-1819.
42. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000;84(5):775-778.
43. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin: nature or nuture? Clin Pharmacol Ther. 2001;70(2):159-164.
44. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690-1698.
45. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002;72(6):702-710.
46. Linder MW, Looney S, Adams JE III, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002;14(3):227-232.
47. Kamali F, Khan TI, King BP, et al. Contribution of age, body size, CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004;75(3):204-212.
48. Wadelius M, Sörlin K, Wallerman O, Moia M, Mannucci PM. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics. 2004;4(1):40-48.
49. Peyvandi F, Spreafico M, Siboni SM, et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther. 2004;75(3):198-203.
50. Borgiani P, Cicacci C, Forte V, Romano S, Federici G, Novelli G. Allelic variants in CYP2C9 and VKORC1 loci and interindividual variability in anticoagulant dose effect of warfarin in Italians. Pharmacogenomics. 2007;8(11):1545-1550.
51. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 Feb;83(2):312-321. Epub 2007 Jul 25.
52. Obayashi K, Nakamura K, Kawana J, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006;80(2):169-178.
53. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005;7(2):97-104.
54. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008 Apr 15;111(8):4106-4112. Epub 2008 Feb 4.
55. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009 Mar;5(3)e1000433. Epub 2009 Mar 20.
56. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009 Jan;113(4):784-792. Epub 2008 Jun 23.
57. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427(6974):541- 544.
58. D'Andrea G, D'Ambrosio RI, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005 Jan 15;105(2):645-649. Epub 2004 Sep 9.
59. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-2293.
60. Veenstra DL, You JH, Rieder MJ, et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics. 2005;15(10):687-691.
61. McClain MR, Palomaki GE, Piper M, Haddow JE. Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. 2008;10(2):89-98.
62. Schwartz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;58(10):999-1008.
63. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005 Oct 1;106(7): 2329-2333. Epub 2005 Jun 9.
64. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262-270.
65. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91(1):87-94.
66. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1;106(1):135-140. Epub 2005 Mar 24.
67. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P450 2C9 genotype. Thromb Haemost. 2005;93(4):700-705.
68. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005;3(3):137-145.
69. Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007;120(2):181-186. Epub 2006 Oct 17.
70. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007 Apr;7(2):99-111. Epub 2006 Sep 19.
71. Anderson JL, Horne BD, Stevens SM, et al; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 Nov 27;116(22):2563-2570. Epub 2007 Nov 7.
72. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin [published correction appears in Clin Pharmacol Ther 2008;84(3):430]. Clin Pharmacol Ther. 2008 Sep;84(3):326-331. Epub 2008 Feb 27.
73. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008 Mar;83(3):460-470. Epub 2007 Sep 12.
74. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(80):753-764.
75. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007 Mar;121(1):23-34. Epub 2006 Oct 18.
76. Wen MS, Lee MT, Chen JJ, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther. 2008 Jul;84(1):83-89. Epub 2008 Jan 9.
77. Kimes M. Medco's big bio bet: the company that manages your drug benefit also wants to get into your genes. Fortune 500. October 24, 2008. http://money.cnn.com/2008/10/24/news/companies/kimes-medco.fortune/index.htm. Accessed September 4, 2009.
78. Harvard's warfarin dose study will analyze cost/benefit of using genebased dosing. Genomeweb Pharmacogenomics Reporter Web site. http://www. genomeweb.com/dxpgx/harvards-warfarin-dose-study-will-analyze-costbenefit-using- gene-based-dosing. Accessed September 4, 2009.
79. Could genetics improve warfarin dosing? New research says yes for now. National Insitute of General Medical Sciences Web site. http://www.nigms .nih.gov/News/Results/Warfarin02182009.htm. Accessed September 4, 2009.